How are MANE strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the MANE strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 100.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$2,280.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a MANE strangle?

The breakeven for the MANE strangle priced on this page is roughly $82.20 and $137.80 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The MANE market-implied 1-standard-deviation expected move in the same options snapshot is approximately 28.90%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current MANE implied volatility affect this strangle?

Current MANE ATM IV is 100.80%; IV rank context is unavailable in the current snapshot.

MANE Strangle Strategy

MANE (Veradermics, Incorporated), in the Healthcare sector, (Biotechnology industry), listed on NYSE.

Veradermics, Incorporated functions as a biopharmaceutical enterprise focused on devising pioneering therapeutic interventions for various skin and cosmetic disorders. The company's development pipeline includes treatments for Pattern Hair Loss (PHL), impacting both adult and pediatric demographics. A flagship offering is VDPHL01, an orally administered, non-hormonal medication specifically for chronic hair loss management in both male and female patients with PHL. Furthermore, Veradermics is progressing with VDMN, an innovative dissolvable microarray patch technology employing immunotherapy for common warts. Its research also extends to VDAA for addressing alopecia areata, and VDMC, aimed at molluscum contagiosum. Collectively, the firm's product candidates target conditions such as androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis.

MANE (Veradermics, Incorporated) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $4.56B, a beta of 1.35 versus the broader market, a 52-week range of 32-131.24, average daily share volume of 689K, a public-listing history dating back to 2026, approximately 24 full-time employees. These structural characteristics shape how MANE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.35 indicates MANE has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.

What is a strangle on MANE?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

MANE snapshot

As of August 14, 2026, spot at $111.50, ATM IV 100.80%, expected move 28.90%. The strangle on MANE below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.

Why this strangle structure on MANE specifically: IV rank is unavailable in the current snapshot, so regime-based timing for MANE is inferred from ATM IV at 100.80% alone, with a market-implied 1-standard-deviation move of approximately 28.90% (roughly $32.22 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated MANE expiries trade a higher absolute premium for lower per-day decay. Position sizing on MANE should anchor to the underlying notional of $111.50 per share and to the trader's directional view on MANE stock.

MANE strangle setup

The MANE strangle below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With MANE at $111.50 on that close, the first option leg uses a $115.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed MANE chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 MANE shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$115.00	$12.40
Buy 1	Put	$105.00	$10.40

MANE strangle risk and reward

Net Premium / Debit: -$2,280.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$2,280.00
Breakeven(s): $82.20, $137.80
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

MANE strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on MANE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$8,219.00
$24.66	-77.9%	+$5,753.78
$49.31	-55.8%	+$3,288.57
$73.97	-33.7%	+$823.35
$98.62	-11.6%	-$1,641.86
$123.27	+10.6%	-$1,452.92
$147.92	+32.7%	+$1,012.30
$172.58	+54.8%	+$3,477.51
$197.23	+76.9%	+$5,942.73
$221.88	+99.0%	+$8,407.94

When traders use strangle on MANE

Strangles on MANE are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MANE chain.

MANE thesis for this strangle

The market-implied 1-standard-deviation range for MANE extends from approximately $79.28 on the downside to $143.72 on the upside. A MANE long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. As a Healthcare name, MANE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to MANE-specific events.

MANE strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. MANE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move MANE alongside the broader basket even when MANE-specific fundamentals are unchanged. Always rebuild the position from current MANE chain quotes before placing a trade.

Frequently asked questions

What is a strangle on MANE?: A strangle on MANE is the strangle strategy applied to MANE (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With MANE stock at $111.50 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed MANE chain strike and the premiums come straight from that session's bid/ask midpoint.
How are MANE strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the MANE strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 100.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$2,280.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a MANE strangle?: The breakeven for the MANE strangle priced on this page is roughly $82.20 and $137.80 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The MANE market-implied 1-standard-deviation expected move in the same options snapshot is approximately 28.90%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on MANE?: Strangles on MANE are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the MANE chain.
How does current MANE implied volatility affect this strangle?: Current MANE ATM IV is 100.80%; IV rank context is unavailable in the current snapshot.